Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and manufacturing services for nasal sprays; the CDMO also offers services for other dosage forms.
In addition to contract work, Basic Pharma notes that it has a number of its own nasal sprays available for licensing. According to the company’s web site, Basic Pharma’s portfolio includes almost a dozen products for nasal delivery, including azelastine / fluticasone, mometasone, oxymetazoline, and xylometazoline nasal sprays.
Basic Pharma CEO Bob Kool commented, “For more than twenty years, we have built Basic Pharma together with a highly committed team and loyal customers. It was important to me to find a partner that genuinely understands our company, values our employees and shares our ambitions. In SHS Capital, we have found a highly experienced and specialized investor that wants to build on everything we have developed together. This will enable us to pursue the growth and long-term success of Basic Pharma in a focused manner.”
SHS Capital Partner Cornelius Maas said, “Basic Pharma is exactly the type of company we look for: a specialized European healthcare champion with a differentiated business model, proprietary dossiers and significant untapped international potential. We look forward to supporting the team in the next phase of growth, organically and through selective acquisitions.”
Read the Basic Pharma press release
